Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Merck Sharp & Dohme (MSD)

Status: Terminated

Conditions: Hepatitis C, Chronic; Hepatitis C

Treatments: Biological: PegIntron pen (peginterferon alfa-2b; SCH 54031); Drug: Rebetol (ribavirin; SCH 18908)

Study type: Observational

Funder types: Industry

Identifiers

NCT00705107

P04247

Details and patient eligibility

About

Adherence to the prescribed treatment regimen with PegIntron and Rebetol affects the chance of achieving a sustained virologic response in patients with hepatitis C. The objective of this study is to evaluate the proportion of patients who complete treatment with PegIntron pen and Rebetol while participating in a patient assistance program. The patient assistance program can consist of prophylactic treatment (eg, with growth factors, psychiatric medications) or other interventions (eg, psychotherapy, patient support groups, visiting nurse, nurse telephone calls, educational literature).

Enrollment: 267 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treatment-naïve patients with hepatitis C
• Patients treated with PegIntron pen and Rebetol
• Patients receiving patient assistance program

Exclusion criteria

• Not applicable

Trial design

267 participants in 1 patient group

All Treated Patients

Description:

All patients participating in the study

Treatment:

Drug: Rebetol (ribavirin; SCH 18908)

Biological: PegIntron pen (peginterferon alfa-2b; SCH 54031)